It started with a belief

Octapharma was founded 40 years ago to provide hemophilia patients with a safer, higher-quality factor VIII (FVIII) concentrate.

News & stories

Check out our latest stories

Journal of Clinical Immunology Publishes Octapharma USA Research on cutaquig® Evaluating PI Treatment Options

Octapharma USA Grant Supports PANS/PANDAS Education Event at NHIA Conference March 27 in Washington, D.C.

Octapharma USA Research at AAAAI: cutaquig® Study at Higher Infusion Rates Presented

Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement

Patient engagement

Octapharma takes an active role in our community

We sponsor and support organizations worldwide.

Learn how we engage with patients

Our products

Products

Learn more about our products to treat rare diseases and other coagulopathies and bleeding disorders.